FY2024 EPS Forecast for TG Therapeutics Increased by Analyst

TG Therapeutics, Inc. (NASDAQ:TGTX) – Investment analysts at HC Wainwright raised their FY2024 earnings per share estimates for shares of TG Therapeutics in a research report issued to clients and investors on Wednesday, January 15th. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will post earnings per share of $0.13 for the year, up from their previous forecast of $0.07. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.07 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q4 2024 earnings at $0.13 EPS, FY2026 earnings at $2.24 EPS and FY2027 earnings at $2.93 EPS.

Other analysts have also recently issued research reports about the stock. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 7th. Finally, TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Stock Up 1.4 %

Shares of NASDAQ TGTX opened at $29.55 on Friday. TG Therapeutics has a 52-week low of $12.84 and a 52-week high of $36.84. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a market cap of $4.60 billion, a P/E ratio of -295.47 and a beta of 2.24. The firm has a 50 day moving average price of $31.73 and a 200 day moving average price of $25.74.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics’s quarterly revenue was down 49.4% on a year-over-year basis. During the same quarter last year, the business posted $0.73 EPS.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,358 shares of company stock valued at $781,497. 10.50% of the stock is owned by insiders.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. NBC Securities Inc. lifted its holdings in TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares during the last quarter. Blue Trust Inc. raised its position in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares during the period. ORG Wealth Partners LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth about $53,000. Values First Advisors Inc. bought a new stake in shares of TG Therapeutics during the 3rd quarter worth about $58,000. Finally, GAMMA Investing LLC grew its stake in TG Therapeutics by 562.4% in the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 2,171 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.